The Cross-Section of Law, Technology, and Innovation
Law students, practicing attorneys, and industry professionals in today’s business environment regularly encounter complex legal issues as practitioners and policy makers at the cross-section of law, technology, and innovation. Recognizing and effectively addressing these issues are increasingly paramount to their success and the delivery of the best possible work product and client service. That is one of the reasons that Gibbons endowed $1 million to the Seton Hall University School of Law to establish the Gibbons Institute of Law, Science & Technology. This gift, which is among the largest donations to a law school by a New Jersey law firm, provides funding to assist the law school in educating and training the next generation of attorneys and other professionals in the technology and scientific communities to address the complex issues they face in the 21st century. The Institute also draws on the experience and knowledge of Gibbons attorneys, as well as leading experts in the area, to provide resources and support to the technology and scientific communities through publications, symposia, and events.

A Forum on Law and Technology Issues
The Gibbons Institute is a forum for lawyers, judges, scientists, and government officials to discuss the legal, political, and social problems that will continue to arise as scientific and technological changes challenge existing laws and legal institutions. With the Gibbons Institute, Seton Hall Law School has the capability to train professionals in health and intellectual property law and advance its J.D. and M.S.J. degrees to better meet the needs of industries facing cutting-edge technological and associated legal challenges. The Institute also allows the university to introduce an LL.M. degree in intellectual property law; to support special events, lectures, and communications efforts; and establish itself as a premier school in the field of Intellectual Property. With New Jersey as a hub of IP law – given the number of technology companies headquartered in the state, outstanding engineering and medical schools, proximity to New York, and sophisticated bench at both the district court and state levels – the Gibbons Institute can serve as a center for excellence to education, train, and engage students and practitioners alike on the range of related issues.

Several prominent pharmaceutical companies, including Schering-Plough Corporation, sanofi-aventis, Johnson & Johnson, and Bristol-Myers Squibb, designated an additional $8.1 million in corporate gifts for the establishment of The Center for Health & Pharmaceutical Law at Seton Hall Law School.

The Gibbons Institute of Law, Science & Technology supports four key goals:

  • Faculty research and scholarship to identify and evaluate solutions for the emerging challenges facing both the public and private sectors that result from rapid innovation in the life sciences and technology industries.

  • Ongoing education and training of law students, attorneys, and industry professionals to further their own efforts to recognize and resolve these challenges.

  • Continuing legal education for practicing attorneys and the judiciary, in connection with news, trends, and developments in intellectual property.

  • Collaboration with life sciences companies, healthcare providers, technology entities, and other public institutions and private businesses, to help each other address these challenges.
The Gibbons Institute supports various degree and certification programs at Seton Hall Law, including a J.D. degree concentration in Intellectual Property Law; a Master of Science in Jurisprudence (M.S.J.) degree in Intellectual Property Law, for non-attorneys working in health or technology related jobs; Master of Laws (LL.M.) degree in Intellectual Property; and an online graduate certificate in Pharmaceutical & Medical Device Law & Compliance, for practicing attorneys and healthcare professionals and administrators.

The Gibbons Institute curriculum is designed to meet the needs of law students, practicing attorneys, and jurists, as well as healthcare, life sciences, and technology industry professionals, who all must keep abreast of the many rapidly evolving technological issues shaping their professions. The slate of programs presented by the Gibbons Institute, featuring federal and district judges from New Jersey, New York, Pennsylvania, and Delaware, in the most recent calendar year includes:

  • “Justice at Stake? Patent and Other Complex Litigation,” which focused on the adverse effects of sequestration, budget cuts and federal judicial vacancies.

  • “Federal Circuit Year in Review,” which reviewed key intellectual property issues that were decided by the Federal Circuit over most recent 18 months.

  • “Managing Counterfeiting Issues in the Pharmaceutical Industry,” which identified practical anti-counterfeiting strategies and discussed how drug companies can develop and implement tailored “best practices” to deter and combat counterfeiters.

  • “USPTO Patent Post-Issuance Proceedings Under the America Invents Act – A New Frontier,” which addressed post-grant proceedings under the American Invents Act (AIA), from both the patent owner’s and challenger’s perspectives, as well as discovery and other new rules of practice before the Patent Trial and Appeal Board (PTAB).

  • “Navigating the Biosimilars Landscape,” which featured biotech and pharmaceutical industry leaders, outside counsel, and faculty members specializing in the Biosimilars arena and provided key insights into the evolving biosimilars landscape, including litigation under the Biologics Price Competition and Innovation Act, the patentability of monoclonal antibodies and the impact of the America Invents Act, and the Food and Drug Administration’s regulation of biosimilars.

For more detailed information about Gibbons Institute programming, please see